ᇨᅕᆒᆊᄱᆞᄬᆡᇞᇴᆡᄡᆍᇻᅎᆇᄚᆱᄭᄢᄡᄢᄢᄳᇑᇶᇅᇹᆠᅐᅌᆣᆙᆥᅋᆘᅋᅸᄼᆙᇑᇰᆙᆖᆙᅎᆖᅣᄲᇄᇴᆙᄱᄱᇣ ᇏᅙᆠᅌᆂᅕᇢᇦᅌᅌᅆᅊᇃᆙᇛᇑᅝᅸᅚᅕᇏᅌᅌᇓᄱᇨᅝᅌᅸᆘᅆᇉᆊᆇᄷᆘᅌᆖᅓᄼᅌᄮᅌᆘᆙᅝᅸᅆᅝᆃᆥᇞᄱᆠᆙ ᄱᇊᆙᄱᄱᇣᆉᆘᆇᇣᇔᄫᇸᇰᆇᇊᇊᇊᇊᅚᇥᄚᇃᇗᄢᆀᇪᅐᆙᅙᄷᇹᆙᅕᄝᆄᆀᆔᆘᆮᄫᆅᇆᆅᄿᆂᇏᆸᆔᆥᆙ



14th EBF Open Symposium Science – Our Universal Language

EBF feedback to industry and FDA on FDA Bioanalytical Method Template

Luca Ferrari and Tom Verhaeghe, on behalf of the EBF

25 November 2021, Barcelona

EBF Background information

In Sept 2019 the FDA published a Guidance for Industry.

It contains ready to use templates to submit BA method summaries used in clinical pharmacology studies for NDAs/BLAs, as part of the Common Technical Document (CTD) for the Registration of Pharmaceuticals for Human Use.

A FotP survey was organized in 2020 to collect feedback on the interpretation and willingness to adopt this guidance.

Bioanalytical Methods Templates

Guidance for Industry

Technical Specifications Document

For questions regarding this technical specifications document, contact CDER at <u>cder-edata@fda.hhs.gov</u>.

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

> September 2019 Technical Specifications





Nine questions were selected to investigate whether:

- this guidance had been adopted within the EBF community
- comments had already been received for NDAs/BLAs
- this technical document was considered to be making other filings difficult and conflicting with ICH M10
- this topic should have been further discussed at the EBF

35 responses were received

Feedback by most responders highlighted:

- Willingness to fully implement the guideline in the future
- Desire to have this topic further discussed at the EBF, in particular to have some clarity/agreement on how to compile the tables





A team was established in October 2020:

Luca Ferrari Tom Verhaeghe Lene Andersen Elke Zwanziger Eva Dam Christoffersen Tobias Haslberger Berthold Lausecker (Roche)
(Janssen)
(Orphazyme)
(Roche)
(AscendisPharma)
(Abbvie)
(Az-Biopharm)

9 TCs were organized



Objectives of the Team

- Review the FotP survey results, collect feedback on experience gained in recent filings
- > Thorough evaluation of the technical requirements defined in the guideline

Action plan:

- 1. To generate an example document: tables populated with real study data, including validations and clinical BA studies
- 2. To prepare a guide providing information on the way the summary tables should be compiled



Example tables

> The team decided to include the following data:

- two methods/validations
- two clinical studies
- one cross validation
- 2 analytes for CC, 1 analyte for LBA assays
- Both Chrom & Ligand Binding Assays were considered



- The preliminary outcome was presented at the 'All members meeting' in April 2021
- It was decided that example tables and guide would be pressure tested by a second round of review including a larger group of EBF representatives from 17 companies
 - Luca Ferrari, Roche Tom Verhaeghe, Janssen Lene Andersen, Orphazyme Elke Zwanziger, Roche Eva Dam Christoffersen, AscendisPharma Tobias Haslberger, Abbvie Berthold Lausecker, Az-Biopharm

Benno Ingelse, Byondis Matti Kinberg, Synexa Rob Nelson, Covance Martin Rieger, Formycon Jean Mark Gnoth, Bayer Marianne Fjording, Bioagilytix Gwenda Pynaert, Argenx Klaus Pusecker, Merck Sirpa Laakso, Orion Nico van de Merbel, PRA

Table 1: Bioanalytical Method Life Cycle Information

	Method validation #1	Method v	alidation #2	Study#1	Study#2
Analyte	Drug A	Drug A + M	letabolite M	Clinical Study XY	Clinical Study YZ
Validation type	Full validation	Full validatio validation wi validation #1	ith Method	In-study	In-study
eCTD reference number	Add number	Add number		Add number	Add number
Method ID	Method A	Method B		Method A	Method B
Duration of time method is in use	2011-	2014-		Jan 2012 - Dec 2013	Jan 2014 – Mar 2014
Bioanalytical site	Company name	CRO name		Company name	CRO name
Matrix	Human EDTA plasma				
Platform		raphy/mass spectrometry (I covery Electrochemilumine			
Format	CCs: Protein precipitati LBAs: Bridging immur		lated specific antibody a	gainst drug A, detection via Sul	lfo-Tag TM labelled antibody against drug A
Stock reference, lot number, expiration date	Drug A; lot n. XY; expiry date 30 Jun 2012 lot. n. YZ; expiry date 30 Nov 2015	Drug A; lot. n. YZ; expiry date 30 Nov 2015 Metabolite M: Lot.n. WX; retest date 02 Feb 2017	Drug A; lot n. XY; expiry date 30 Jun 2012	Drug A; lot. n. YZ; expiry date 30 Metabolite M: Lot.n. WX; retest date 02	
Calibration range from the lower limit of quantitation (LLOQ) to the upper limit of quantitation (ULOQ)	1.00 ng/mL to 2000 ng/mL	Drug A: 1.00 ng/mL to 2000 ng/mL Metabolite M: 1.00 ng/mL to 2000 ng/mL	1.00 ng/mL to 2000 ng/mL	Drug A:1.00 ng/mL to 20 Metabolite M: 1.00 ng/m	
Matrix study population	Healthy	Healthy and Rheumatoid Arthritis	Healthy	Rheumatoid Arthritis	

CCs: Chromatographic Assays

EBF

LBAs: Ligand Binding Assays



Table 2a: method performance (in validation)

Bioanalytical method validation report name, amendments, and hyperlinks	Method A validation report name, amendments and hyperbolic sector of the	perlinks	
Method description	CCs: (Analytical procedure for the Determination of D followed by Liquid Chromatography with Tandem mas (LC-MS/MS) using a stable isotope labelled/structural LBAs: Serum Bridging electrochemiluminescence (EC antibody against drug A, detection via Sulfo-TagTM la	s Spectrometric De analog internal star L) immunoassay, o	etection ndard. capture via biotinylated specific
Materials used for standard calibration curve and concentration	CCs: Blank human EDTA plasma; 1.00-2.00-5.00-10.0 LBAs: Blank human serum; 0.05*-1.00-2.00-5.00-10.0 (*anchor calibrators)		-
Validated assay range	1.00-2000 ng/ml		
Material used for quality controls (QCs) and concentration	Blank human EDTA plasma; 1.00 (LLOQ)-2.80 (Low) 15600 (Dilution #1)-154000 (Dilution #2) ng/mL	-60.0 (Medium)-1	560 (High)-
Minimum required dilution (MRD)	CCs: Not Applicable LBAs: 1:100		
Source and lot of reagents	CCs: Not Applicable LBAs: Biotinylated antibody A Source: Company X; S	ulfo-tagged antibo	dy B Source: Company Y
Regression model and weighting	CCs: 1/x2 weighted Linear regression LBAs: 5PL Marquardt with 1/Y ² weighting		
Validation parameters	Method summary	validation	Source location
Standard calibration curve performance during accuracy and precision runs	Number of standard calibrators from LLOQ to ULOQ (calibration line in singlicate)	11	Table X in Report Y
	Cumulative accuracy (%bias) from LLOQ to ULOQ Product A *	-4.0% to +3.0%	Table X in Report Y
	Cumulative precision (%CV) from LLOQ to ULOQ Product A *	≤ 2.0%	Table X in Report Y able 2 of Method A Validation report
Performance of QCs during accuracy and precision runs	Cumulative accuracy (%bias) in 5 OCs QCs for product A: Please list *	+1.9% to +7.7%	Table X in Report Y
	Inter-batch %CV QCs for Product A: Please list *	≤ 3.6%	Table X in Report Y
	Total Error (TE) QCs for Product A: Please list *	CCs: NA LBAs: ≤ 21.3%	Table X in Report Y

CCs: Chromatographic Assays	
LBAs: Ligand Binding Assays	

Selectivity & matrix	CCs:	Table X in Report Y
effect	6 lots tested,	
	Bias: -9.6% to +1.0% selectivity	
	Bias: -10.6% to +3.5% matrix effect	
	LBAs:	
	9 out of 10 healthy serum samples: %bias (-9.3) to 11.0% at LLOQ;	
	1 serum sample failed the 25% Bias criterion at LLOQ.	
	9 out of 10 healthy serum samples: %bias (-15.6) to (7.0)% at high QC.	
	1 serum sample failed the 20% Bias criterion at high QC.	
Interference &	CCs:	Table X in Report Y
		Table A in Report 1
specificity	6 lots tested. No interference at RT of analyte or IS.	
	Drugs tested:	
	Drug A: no interference	
	Drug B: no interference	
	Drug C: no interference	
	Interference with Drug A: the blank samples spiked with Dug X at 3300 ng/mL did	
	not contain any peaks at the retention time of Drug A (>20.0% of the LLOQ	Table X in report Y
	calibration standard response) or ISTD (>5.0% of the ISTD peak response in the	
	control zero sample).	
	%Bias at LQC: -6.7 to -4.3	
	Interference for Drug B:	
	Interference for Drug C:	
	LBAs:	
	e.g. describe interference with target:	
	e.g.Structurally related Drugs tested for selectivity:	
	Drug A: no interference	
	Drug B: no interference	
	Drug C: no interference	
	e.g. describe interference with Anti-Drug Antibodies (ADA)	
Hemolysis effect	One lot tested, %Bias: -8.4 to -7.3	Table X in Report Y
-		1
Lipemic effect	One lot tested. %Bias: -3.3 to 5.5	Table X in Report Y
Dilution linearity	Dilution Linearity:	Table X in Report Y
& hook effect	Highest concentration tested: X ng/mL	
	Range of dilutions tested: 1/10, 1/100, 1/1000, 1/5000	
	Highest dilution tested: 1:X	
	Cumulative %bias: -8.6% to 10.0%	
	Cumulative /00las0.070 to 10.070	
	Hook Effect (LM): A hook effect was not observed for the concentrations tested	1
		1
Bench-top/process	(include highest concentration tested)	T 11 N . D
stability	Blood: 4h on melting ice; 4h at room temperature	Table X in Report Y
subury	Plasma: 72h at room temperature	
	Processed samples: 96h in autosampler at room temperature	
Freeze-Thaw stability	4 F/T cycles at -20°C/room temperature	Table X in Report Y
	•	

CCs: Chromatographic Assays LBAs: Ligand Binding Assays



Table 2a: method performance (in study)

Method po	erformance in study#1	
Assay passing rate	100% (7/7)	Table X in Report Y
Standard curve performance	 Cumulative bias range: -1.5% to +2.0% Cumulative precision: ≤ 3.4% CV 	Table X in Report Y
QC performance	 Cumulative bias range: -3.7% to +0.7% Cumulative precision: ≤ 4.0% CV TE: Not Applicable (SM), ≤ 18.0% (LM) 	Table X in Report Y
Method reproducibility	Incurred sample re-analysis was performed in 48/232 (21%) of study samples, and 91.7% of the samples met the pre-specified criteria.	Table X in Report Y
Parallelism	Incurred sample parallelism was performed in 10/232 study samples, and 100% of the samples met the pre-specified criteria. Or: Parallelism was not performed for this study	Table X in Report Y
Study sample analysis/ stability	Maximum frozen storage for STDs/QCs and study samples was 317 days. Samples and STDS/QCs were analyzed within proven frozen stability of 326 days at -20°C.	Table X in Report Y
Standard calibration curve performance during accuracy and precision runs	CCs: 11; 1.00-2.00-5.00-10.0-20.0-50.0-100-200-500-1000-2000 ng/ml LBAs: 11; 0.05*-1.00-2.00-5.00-10.0-20.0-50.0-100-200-500-1000-2000-4000* ng/ml *anchor calibrators	•

CCs: Chromatographic Assays

LBAs: Ligand Binding Assays

Table 2b: method modifications and cross-validations

Bioanalytical method validation report name and hyperlink	Method A and Method B Validation report name	
Changes in method	Transfer to another lab	
New validated assay range if any	Assay range not changed	
Validation parameters	Cross-validation performance	Source location
Standard calibration curve performance during accuracy and precision runs	Cumulative accuracy (% bias) in standard calibrators from LLOQ to ULOQ	see data in validation reports for method A and method B
pi contra la contra l	Cumulative precision (% CV) from LLOQ to ULOQ	see data in validation reports for method A and method B
Performance of QCs during accuracy and precision runs	Cumulative accuracy (% bias) in 5 QCs	see data in validation reports for method A and method B
	Inter-batch % CV	see data in validation reports for method A and method B
	Percent TE	see data in validation reports for method A and method B
Cross-validation	 18 spiked QCs; low-mid-high QCs in 6 replicates Method A: bias +1.3% to +3.6%; CV ≤ 1.4% Method B: bias +3.9% to +8.4%; CV ≤ 7.6% 30 incurred samples; 29 of 30 within ±20% difference, 	Table X in Report Y Table X in Report Y
List other parameters	range -25.8% to +2.9%,	

EBF



Topics for which clarification is needed

General topics:

- 1. The suggested tables are to be included in the CTD section 2.7.1. in docx format, as well as an Appendix in the Summary of Biopharmaceutics located in eCTD 2.7.1. We do not understand why the tables need to be included twice.
- 2. Hyperlinks: is it sufficient to include hyperlinks to the specific reports (assay validation, bioanalytical study) or should hyperlinks to the specific report sections be also included in the summary tables?
- 3. It is not clear whether the tables should only be completed for the drug(s) which are the object of the NDA/BLA or also for other analytes (e.g. DDI probe substrates, for which limited information on the assay lifecycle could be available to the sponsor).



Topics for which clarification is needed (cont.)

Table 1:

1. Should "stock reference" be read as "batch number of the reference standard" or should additional information on stock solutions be included, too?

Table 2a:

- 1. in section 2.0 of the Guidance it is clearly stated that info should be provided "using one method per analyte per table". It is not clear if this is also valid in case of multiple analytes determined using the same method. In this case we would recommend to have only one table per method.
- 2. "Material used for standard calibration curve/QCs and concentration"; is "material" intended as the matrix (e.g. EDTA plasma) or should any additional information, e.g. lot of the reference standard be also provided?
- 3. "Source and lot of reagents": we assumed this is limited to the reagents employed in ligand binding assays, only. Is this a correct assumption?



Topics for which clarification is needed (cont.)

Table 2a (cont.):

- 4. "Cumulative accuracy in 5 QCs"; It is not clear what number "5" refers to. Also, it is not clear what "cumulative" means (e.g. inter-assay?) throughout the document.
- 5. It is not clear what the meaning of "standard calibration curve performance during A&P runs" in the method performance summary is. In the instructions, it is requested to "provide the number of standard calibrators".
- 6. Regarding the stability assessment, it is not clear what level of detail is required: our recommendation is to list only the last accepted stability timepoint, including the related storage temperature.

Table 2b:

- 1. The purpose of this table is unclear. In particular, what is meant with "performance of calibrators and QCs during accuracy and precision runs" as these are not performed as part of cross validations?
- 2. Also, our suggestion is not to populate some of the fields, as most of the information is already provided in Table 1.



Proposed guide

It provides instructions on the way the different fields should be populated

Based on our interpretation of the technical requirements defined in the guideline

Table 1. Bioanalytical Method Life Cycle Information

General recommendations for filling this table:

- Validations should be listed first, followed by the clinical studies supported using these validated methods.
- 2. Include all clinical studies for which PK assessment is performed.
- Group all analytes which can be quantified simultaneously using the same method.
 Limit the information to the drug to be approved and its metabolites; do not include other.
- drugs that were also quantified in specific studies (e.g. probe drugs for assessing drug interaction potential).
- Include any additional information that might be relevant for the submission. However, do not delete any fields defined in the template.

Additional recommendations:

Duration of time method is in use:	Enter start/end dates (month/year) for sample analysis.
Matrix:	Split merged cells in case different matrices are validated or analyzed.
Platform:	Split merged cells in case different assay platforms are adopted.
Format:	Split merged cells in case different assay formats are adopted.
Stock reference, lot number, expiration date	The wording (stock reference) is unclear, however reference standards (not stock solutions) should only be considered.
Synopsis of amendments history:	Consider amendments to any method.

Table 2a. Summary Method Performance

General recommendations for filling this table

- Group information for all analytes that can be quantified simultaneously using the same method.
- Include any additional information that might be relevant for the submission. However, do not delete any fields defined in the template.

Method description:	For chromatographic methods, include the most important characteristics of the assay, e.g. information on the internal standard used (stable isotope labelled o structural analozue) for chromatographic assays.
Materials used for standard calibration curve and concentration	Report matrix used and concentration of calibration standards (including anchor calibrators for ligand binding assays).
Material used for quality controls	Report matrix used and concentration of quality
(QCs) and concentration	controls.
Standard calibration curve	Report inter-batch accuracy and precision from the
performance during accuracy and	A&P runs and list smallest to largest bias and highest
precision runs	CV across all calibration standards.

Performance of QCs during accuracy	Report inter-batch accuracy or precision from A&P
and precision runs	runs and list smallest to largest %bias and highest $CV(TE \text{ for } LBA)$ across all QC levels. Number of QCs (3): change number in case a different number of replicates for each QC level is analyzed.
Selectivity & matrix effect	Different wording can be adopted depending on company SOPs. Consider all co-medications tested for selectivity as part of the method validation. In case the selectivity assessment is study-specific, refer to the bioanalytical report of the study where this was performed.
Interference & specificity	Different wording can be adopted depending on compary SOPs. Consider all co-medications tested for interference as part of the method validation or within specific studies in case the interference assessment is study-specific, refer to the bioanalytical report of the study where this was performed.
Bench-top/process stability	Report stability data in relevant biological matrices (last acceptable time point and temperature).
Freeze-Thaw stability	Indicate number of F/T cycles and related temperatures.
Long-term storage	Report last accepted stability time point, including temperature.
Parallelism	If study specific (using real study specimens) refer to the relevant table of the clinical BA report.
Carry over	Report carry over levels observed. In case carry over is not within specifications, report max value observed (as % analyte response at LLOQ) and that it was mitigated.

Assay passing rate	List number of accepted runs/total number of runs performed in the sample analysis phase; include ISR runs in case ISR is assessed in separate ones.
Method reproducibility	Report number of samples reanalyzed/total number (%) and % of ISR samples meeting acceptance criteria.
Study sample analysis/ stability	Report maximum storage period for STDs/QCs/study samples and proven stability data.
Standard calibration curve performance during accuracy and precision runs	Provide the number and concentrations of calibration standards (including anchor calibrators for ligand binding assays), as accuracy and precision are not assessed for calibrators in sample analysis runs. However, the provided information does not match with the request defined in the row header.

EBF An example of the information provided in the guide

Table 2a: Summary of method performance (in study)

Standard calibration curve performance during accuracy and precision runs

No P/A runs are performed within clinical studies

	Standard calibration curve performance during accuracy and precision runs	Provide the number and concentrations of calibration standards (including anchor calibrators for ligand binding assays), as accuracy and precision are not assessed for calibrators in sample analysis runs. However, the provided information does not match with the request defined in the row header.
--	---	---



Where we are now

Communication to the FDA:

- An official letter was sent to the agency (att. Brian Booth) from the EBF account on 27 Oct 2021. It contained the list of topics for which clarification was deemed necessary.
- The example tables and the guide were also included as addenda.

Communication with AAPS:

Faye Vazvaei (on behalf of the AAPS) will present on this topic at the OS in December.

Posting on the EBF website:

The example tables and the guide will be posted on the EBF homepage (www.e-b-f.eu).

Hevenisen BBC 5-1000 Sourcein	Forum une	EB	5		
5-1000 Snapels Delgium		/			
Brussels, Ochder 28 th 2021 To Dr. Brian Boeth					
The European Ricanalysis For Bicanalysis community. It co Ottos: Children I	um vie (189), a non profit organization which brings together the reartly counts 75 member companies; More info can be found on	European a fra EBF web	nagistad alta		
Large of our question:	silana in Induity - Tedrical Januffacture Document on Rosen				
Templates					
Mathem Templates. This put to the Agency, are set of the 1 This information is surmaily a methods" and the suggested Sommary of Biopharmaceutic The ISP appreciates the effect from ISP appreciates the effect found difficult to understand	is in this initialities, alread is harmonice the way method surrowry 87 members reported their difficulty in filling the tables, as some o or were perceived as ambiguous and sometrime protects different or of the source is a definition.	l'ineral/h costicals ho el enociete e Appendia dels decold f de indexed t interpretet	ud methods r Human Das, d analytical in the Dark were for, thereby calls as	Europano Silamalysis Form Havashana 560 15-1000 Branata Belgion	•••• E
hear that our member comp leased on this feedback, the P server al pharmaceutical comp clarification was deemed neu- discounting the specifics for ear	amine driver part clarifying fundback from the Agence spore submit W formed a tasen to exclusive the content of the Told Galdeline, is seening and COS, to the spirit of the TOL (the team provided a flat means, Beddes, the team provided an exemption of the complete di- da of them. Tones are provided an exemption of the complete di- st of them. Tones are provided to team by a second model of real-	start, shafing man	tion from	Addendum 02: EBF interpre- team discusions in 2003-202	tation and readmap for filling out the table
prop-of BH representatives	from 17 companies.			Table 1. Bioambytical Metho	ed Life Cycle Information
The suggested lights are	res, for which feedback from the agency would be appreciated, in the finituded in the CTD antition 2.7.1. In door formul, as well as aution located in eCTD 2.7.1. We do not understand why the fable	an Aspendia	in the	Queeral recommendations for SI	ing this table;
 Neperinks, is it sufficient hyperbolic is the specific list in clear adverted also for other analytes (p available to the sported) Table 1: 	It to include importants to the specific reports (ansay welf-defaux, bin report sections the above hand of the converse facility of a table board only the complete the track angle which are then at a good product and and the complete the track angle which are the set of the sector of the sector of the sector of the sec- tor of the sector of the sector of the sector of the sec-	enskyrkal sto (se t of the b sy theogene o	dyl or should CA/NA or ould be	 tablené satioli. Incluée el clinical trateir. Orang all analyses shield: Linit des information tr deug dans vene also que deug dans vene also que 	and first, full-tened by the clinical studies supported a for which JTK assessment is performed, can be quantified simultaneously using the same in the drug to be approved and its methods, or a sur- stifted in queckle studies (e.g. purche drugs far asses- farmation that might be solvent for the submission in the tamping.
on stock solutions b	e included, too? Wetwine <u>Integra (Vetar Les</u> Contect <u>integra Les</u>			Additional recommendations:	
	Cartact while of ey			Duration of time method is in	
				Matrix	Spitt merged cells in case different ma
				Addition.	validated or analyzed.
				Pietlera: Format:	validated or analyzed. Spät menged cells in case different av adoprat. Spät menged cells in case different av adoprat.
				Plastera:	validated or makytesi. Split neerged cells in case different av adopted. Split neerged cells in case different av adopted. The working (stock reference) is unch reference inselateth (ast stock seletion be casedored.
inngnan Bisaralysh Person Rate Jie & Cas			EBF	Pineform: Permat: Steck reference, for sambles, expiration date	valatané or autypaí. Splat naroje čísli k cas dožitena za akopad. Splat naroje čísli k cas dožitena za akopad. Da rozding úsek réferenci i kol defence i staladní úse kolido belence istaladní úsek sobi oklido belence istaladní úsek sobi oklido belence istaladní kas koli oklido
Table 1	a Summary Marked Performance			Plantena: Formar: Deck reference, Int mander, capitation data Sympole of anondancem histo	validated or and/pad. Split marged of the Local defineme are adopted. Split marged of the Local defineme are adopted. The working (brock reference) is unch reference and the local torck solution is demonstrated by the local torck solution is
Table 2 Table 2 to end "" table delinities of pro- mentioned and below methods and a	 Summary Method Performance into a useful Aligned points or useful sam applicable for prints And determined and applicable 	3153(prod	-	Partners: Foreas: Deals reference to the second sec	visites in majora. Spirmage clinic case Alfreenz are spirmal. Spirmage clinic case Alfreenz are spirmal. Date working (sinch referenze) is undi- referenze same failed in air sinch valence () second and an extension in a series working. The second are spirmal and a sinch assessed on the second and a sinch assessed on the second method and the second are spirmal and a sinch assessed to a sinch and and the second assessed on the second second and a sinch assessed on the second assessed on the second assessed on the second assessed on the second second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the
Table 2	a. Sciences y Method Performance there a used a ablined point, we work your methods in Science 1. Indexemption of the science of the science and the science of the science of the science of the science Science of the science of the science of the science of the science of the Science of the science	11330 good	ten min Prophetics 5192 roses a cite	Parterne: Format: Breit, reference, reporting, distribution, distribution, reporting, distribution,	visites in majora. Spirmage clinic case Alfreenz are spirmal. Spirmage clinic case Alfreenz are spirmal. Date working (sinch referenze) is undi- referenze same failed in air sinch valence () second and an extension in a series working. The second are spirmal and a sinch assessed on the second and a sinch assessed on the second method and the second are spirmal and a sinch assessed to a sinch and and the second assessed on the second second and a sinch assessed on the second assessed on the second assessed on the second assessed on the second second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the
Table 2 Table 2 to end "" table delinities of pro- mentioned and below methods and a	 Summary Method Performance into a useful Aligned points or useful sam applicable for prints And determined and applicable 	31330 grad mine ning 70 tortice 8.0 M sphere via bin min ling A	lara sente Prospetation di Prospetatio	Partners: Foreas: Deals reference to the second sec	visites in majora. Spirmage clinic case Alfreenz are spirmal. Spirmage clinic case Alfreenz are spirmal. Date working (sinch referenze) is undi- referenze same failed in air sinch valence () second and an extension in a series working. The second are spirmal and a sinch assessed on the second and a sinch assessed on the second method and the second are spirmal and a sinch assessed to a sinch and and the second assessed on the second second and a sinch assessed on the second assessed on the second assessed on the second assessed on the second second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second as the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the second assessed on the second assessed on the second assessed the second assessed on the
Table 2 Table 2 We may "hid addition pro- bination result and addition result and addition result and addition result and addition results and addition of the seather addition of the seather	Community Michael Performance The Annual State of the State o	11330 good men ang P. Sector J. C. M sphere eta hin me dag A CORE 2000 70 500, 2000 70	hata militi Prospection Striftowings a califi inglated quarks Original Bioletter signal.	Partners: Foreas: Deals reference to the second sec	video i maine de la constante
Table 2 or new " Ad additions on Bandwood and the second second bandwood and the second second bandwood and the second second bandwood and the second second operations of the second second second second second second second second second second second second second second second	Someany Michel Performance The American Stream St	11330 good men ang P. Sector J. C. M sphere eta hin me dag A CORE 2000 70 500, 2000 70	hata militi Prospection Strifforwings a califi inglated quarks Original Bioletter signal.	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
Table 1 Table 1 Table 2 Table	Sources y Michael Performance Michael Perform	3133(gend more using 7- more action 21- system 41-34 system 41-34 sys	he's sain Propholes 6559 sector a cide indated questle Origital 064007 spint. 000 (20biles 11)	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
Table 1 Table 2 Table	Sources y Michael Performance Michael Perform	3133(gend more using 7- more action 21- system 41-34 system 41-34 sys	he's sain Propholes 6559 sector a cide indated questle Origital 064007 spint. 000 (20biles 11)	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
The second secon	Sourcesty Michael Performance Michael Performance Sourcesting and the state of the	3133(gend more using 7- more action 21- system 41-34 system 41-34 sys	he's sain Propholes 6559 sector a cide indated questle Origital 064007 spint. 000 (20biles 11)	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
CREATER ALL ALL ALL ALL ALL ALL ALL ALL ALL AL	A second Model Polynomial A second	3133(good more using 7- more action 21- system 41-34 system 41-34 sys	helds metri Prospitation 50% of the section of the 10% of the 10% of the section of the 10% of th	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
The second secon	A searcy ladded Performance The analysis of the standard search and t	11330 grad over a los 2 - 50 spinor et los 2 - 50 s	han	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
Conception of the second secon	A second Model Polynomial A second	133 X paral error angle 12 status 12 0 spinor cha th constant 22 0 spinor cha th constant 23 0 second constant second	here vesta Providention (Soff vesta et al. (a) And Providention (Control of a state of a state (Control of a state of a state (Control of a state of a state of a state (Control of a state of a state of a state (Control of a state of a state of a state (Control of a state of a state of a state (Control of a state of a state of a state (Control of a state of a state of a state of a state (Control of a state of a state of a state of a state (Control of a state of a state of a state of a state of a state (Control of a state	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
The second secon	A second Victor Professional and the second an	11330 grad over a los 2 - 50 spinor et los 2 - 50 s	here The population of the second s	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
Conception of the second secon	Security Mind & Polymers and a security of the security o	133 X paral error angle 12 status 12 0 spinor cha th constant 22 0 spinor cha th constant 23 0 second constant second	International Society of Society	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
The second secon	A second Victor Professional and the second an	1113 grant mercening in series 4.5 M series 4.5 M series 4.6 M series	here The population of the second s	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
The second secon	 State of Scholarses State of Scholarses<	111 X grad men and 0 gapse is 0.10 gapse is 0.10 men and 0.11	International Society of Society	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a
The second secon		1333 g pend mere a legit fi - gener da bits fi - da bits in - da bits	Arabier Providence Arabier Statistics Arabier Statistics Arabier Statistics Arabier Statistics Arabier	Partners: Foreas: Deals reference to the second sec	video i majos. Spisa as con con actives as spisa as con con actives as spisa as con actives as spisa as a constraint as an actives as as a spisa. Constraint as an actives as an actives as the constraint as constraint as a spisa and constraint as a spisa a



Acknowledgements





Contact Information

Questions: info@e-b-f.eu

